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Summary
Neurotoxicity is an important side effect of lithium therapy. It has been
described both in lithium mono-therapy with normal serum levels or with
toxic levels, and in combined treatment with other therapeutics, particularly
with antipsychotics or antidepressants. This paper reports three different
cases of patients with affective disorders who developed severe encephalo-
pathy under combined lithium treatment. In case 1, neurotoxicity occurred
under a combination of lithium and risperidone. Case 2 reports a patient who
developed neurotoxic symptoms under lithium, trazodone and bupropion.
Finally in case 3, neurotoxicity developed under the combination of lithium
and tranylcypromine.
Neurological examination, psychopathological state and the results of
EEG and serum analysis are presented. Besides the clinical state, EEG was
shown to be the most important investigational method for both the acute
phase and the follow-up.
Neurotoxicity caused by different combination therapies with lithium
and antipsychotics or antidepressants probably results from different inter-
action mechanisms which are discussed in the paper. A malignant neuro-
leptic syndrome MNS should be considered as possible differential diagno-
sis in treatment with lithium and neuroleptics. Somatic co-morbidities and
co-medication as well as the patient’s age might influence the possibility of
the occurrence of neurotoxicity during lithium therapy. Therapeutic alter-
natives such as mono-therapy with antidepressants or antipsychotics should
be considered.
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Introduction
Lithium is still considered an essential therapy in the treat-
ment of affective disorders, and because of its high effec-
tiveness it is also believed to be one of the most important
strategies.
Since the introduction of lithium therapy [1], a great
amount of literature has been published on clinical expe-
rience with the neuropsychiatric side effects of lithium.
Acute lithium toxicity has a mortality of 15%, and 10% of
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survivors suffer permanent neurological sequelae that are
largely unpredictable, although persons with the longest
and most clinically severe intoxication are probably at a
higher risk [2].
Neurotoxic side effects can occur with normal serum
levels [3, 4], but typically also with lithium levels over
1.5 mmol/l in the sense of an intoxication, with the corre-
sponding symptoms. Only a few cases showing symptoms
of acute delirium with sudden onset after exposure to lith-
ium over decades with therapeutic lithium levels in the
sense of a pseudo-dementia with a reversible course have
been described [5]. Intoxications resembling Creutzfeld-
Jacob disease have also been reported [6]. There has been
a controversial discussion about the so-called SILENT-syn-
drome [7], the syndrome of irreversible lithium-induced
neurotoxicity. Newman and Saunders [8] postulated in
1979, according to their own case reports, that neurotoxic-
ity related to lithium occurs more often in clinical practice
than has been published. A few articles have reported cor-
tical myoclonus even with therapeutic doses of lithium [9].
A hypersensitivity of the CNS towards lithium therapy has
often been thought to be responsible for this phenomenon
[10]. In addition, neuropsychiatric complications, and above
all encephalopathic syndromes (clinical, electroencephalo-
graphical), occurred more often under the combination of
lithium with high-potential neuroleptic drugs (typical ones,
especially haloperidol).
In the following paper, we report on three patients who
showed neurotoxic encephalopathy under combined treat-
ment with lithium and antipsychotics or antidepressants.
Case reports
Case 1: lithium and risperidone
History
A female patient aged 60 with a schizoaffective disorder
(ICD-10: F25) was transferred to the University of Zurich
Psychiatric Hospital, because of a psychoorganic residual
state under combined treatment with lithium and risperi-
done.
At the age of 35 she was diagnosed with a schizoaffec-
tive disorder and had suffered several episodes in the past
which had been treated with various antidepressants and
neuroleptics.
A prophylactic treatment with lithium had always been
tolerated without complications for a period of more than
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two decades. As far as we knew, she did not suffer from any
somatic disorders.
Follow-up
Due to paranoid fears, various neuroleptics had been given.
Severe side effects occurred such as akathisia under olan-
zapine and haloperidol. Finally, risperidone was intro-
duced and increased to 6 mg/d in six days while she was
still treated with lithium. There were no other co-medica-
tions after haloperidol and olanzapine had been stopped.
Lithium levels were not measured at this time of the treat-
ment. Under this medication, hypomimia, hypersalivation
and ataxia were observed. Within two weeks, rigor in all
extremities became manifest and febrile temperatures were
recorded. Blood samples showed an elevation of CK levels
(953 U/l; normal range <145 U/l) and low sodium levels.
Risperidone and lithium were stopped. The patient showed
an acute neuropsychiatric state with severe cognitive deficits
and a severe akinetic extrapyramidal syndrome.
The clinical state gradually began to improve after
withdrawal of the psychopharmaceutics. CK levels nor-
malised within three weeks after stopping lithium and
risperidone, but severe neuropsychological deficits (lack of
attention, concentration, memory and especially logical-
abstract thinking) persisted.
Neurophysiology
An EEG investigation in the acute state showed a severe
change in basic activity which can usually be seen in the
case of a diffuse encephalopathy. Follow-up EEGs showed
a relatively frequent paroxysmal change of pattern with
Frontal Intermittent Rhythmic Delta Activity (FIRDA),
briefly preceded by fast activity with a fronto-precentral
maximum and later on a change in the characteristics of the
1/s sharp-slow-waves. This pointed to severe disturbances of
the vigilance-controlling thalamo-retikular structures.
Finally after stopping the medication (only a low dose
lorazepamwas given), the EEG showed a clear improvement
with only slight changes in general activity.
Further course
After four weeks, neuropsychological functions improved.
Psychomotoric unrest persisted, as did difficulties in every-
day tasks due to an impairment of frontal lobe functions.
Depressive symptoms could be improved under medication
with citalopram and lamotrigine, and psychomotoric unrest
ceased under therapy with quetiapine which was tolerated
without side effects.
Case 2: lithium, trazodone and bupropion
History
A 72-year-old male patient with a recurrent depressive
disorder (ICD-10: F33.2) was transferred to the University
of Zurich Psychiatric Hospital after an attempted suicide. He
had been diagnosed 15 years previously and had a history
of three depressive episodes. In the past he had been treated
with various antidepressants and antipsychotics. One year
before the reported event, he had started treatment with
a combination of lithium, trazodone and quetiapine. Six
months previously, the patient had started treatment with a
combination of DOPA and benserazide because of a tremor.
Idiopathic Parkinson’s Syndrome was ruled out following a
neurological examination. Due to side effects (e.g., weight
gain), lithium and quetiapine were stopped six weeks be-
fore admission.
Follow-up
Due to a severe depressive state, the patient was initially
treated with trazodone, and subsequently lithium was re-
introduced. Blood samples showed normal lithium levels
(0.9 mmol/l; normal range 0.5–1.3 mmol/l) and creatinine
level (119mcmol/l; normal range 50–120mcmol/l). Because
of persisting depressive symptoms the antidepressant bupro-
pion was added. After an augmentation up to 300 mg of
bupropion and 300 mg of trazodone, within two weeks the
patient showed a delirant syndrome with fluctuating aware-
ness, slow and muddled thinking, visual hallucinations and
ataxia. All the prescribed drugs were discontinued.
Neurophysiology
In the acute state, the EEG showed slight pathological signs
with normal basic activity and a diffuse slowing in the fron-
tal region in the form of dysrhythmical delta-insertions with
a few triphasic-like configurations. These findings were
compatible with a slight metabolic encephalopathy.
A second EEG five days after discontinuation of any
psychotropic medication showed normal results.
Further course
Four days after the manifestation of the acute encephalo-
pathic syndrome and after reduction and subsequent with-
drawal of the medication, the symptoms normalised under
therapy with lorazepam and a low dose of haloperidol.
Finally the patient received treatment with lamotrigine
and fluvoxamine which was tolerated without side effects.
Case 3: lithium and tranylcypromine
History
A 71-year-old female patient with a bipolar II disorder
(ICD-10: F31.8) had been treated with lithium for 19 years.
The patient also suffered from thyroid insufficiency
which was compensated with Eltroxin (0.1 mg). Due to
a therapy-resistant depression – after combined treat-
ment with lithium, venlafaxine and escitalopram –, a
combined treatment with lithium and tranylcypromine
was introduced. Under this medication, encephalopathic
symptoms occurred.
Follow-up
Under 50 mg/day tranylcypromine, lack of concentration,
memory deficits and disorientation occurred as well as
diffuse fears, illusionary confusion and misjudgement. Fur-
thermore, the patient had a dysfunction of balance and
ataxia. There also was an episode of hypertension and the
patient collapsed once. Blood samples revealed elevated
lithium levels (1.0 mmol/l) considering the age of the patient
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and elevated creatinine levels (up to 150mcmol/l, GFR 28.9,
reflecting an already existing renal insufficiency).
Neurophysiology
An EEG investigation in the acute state showed pathological
signs with slight changes in basic activity and a bi-temporal,
left-side accentuated, intermittent functional disturbance
compatible with an encephalopathy (fig. 1). These findings
disappeared in the further course, with the exception of a
slight slowing of the basic activity to 7 Hz.
Further course
As a fluctuating state of deliriumwith disorientation, unrest,
ataxia and illusionary confusion and misjudgement per-
sisted, lithiumwas stopped and tranylcypromine was phased
out. Only diazepam was given briefly. In the further course,
the patient was still disorientated to time and place and
showed apraxia and difficulties in short-term memory.
After a period of one month, the clinical state improved.
The patient was orientated, the walking difficulties normal-
ised and no more apraxia was observed.
Finally, the depressive symptoms also improved under a
combination of lamotrigine, duloxetine and trazodone and
the patient could be discharged in a stable state.
Discussion
Our series of cases shows three examples of neurotoxicity
under a combination of lithium with antipsychotics and
antidepressants.
In the first case, a 60-year-old female patient with
a schizoaffective disorder developed a severe neurotoxic
encephalopathy under the combination of lithium and
risperidone. Based on the clinical symptoms (rapid devel-
opment of the symptoms, extra-pyramidal symptoms, high
temperature, increased CK levels), a malignant neuro-
leptic syndrome (MNS) should also be considered in the
differential diagnosis [11, 12]. MNS has also been described
in the literature under lithium mono-therapy [13]. It has to
be considered that the patient mentioned by Gill et al. took
an intentional overdose of about 40 g lithium. Furthermore,
it is surprising that Gill et al. called this MNS despite there
being no neuroleptic drug involved.
Concerning the interaction between the two drugs,
lithium and risperidone, several case reports can be found
in the literature [14, 15]. The male patient in Boora et al.’s
paper was suffering from bipolar disorder and presented
manic symptoms with psychotic features. The female patient
in Boeker et al.’s report had been suffering from schizoaffec-
tive disorder for decades. All patients developed encephalo-
pathy within a few days after starting the combination of
lithium and risperidone. Similar EEG changes, specifically
slow-wave EEG changes, could be seen in all cases. Whereas
in Boora et al.’s paper the adverse effects were reversed
upon discontinuation of lithium and risperidone, the female
patient in Boeker et al. 2007 and in case 1 improved, but
developed persisting neuropsychological deficits.
In regard to the interaction between the two drugs, the
most important hypothesis put forward is that lithium-
antipsychotic treatment causes neurotoxicity by increasing
dopamine receptor blockade [14]. Both lithium and rispe-
ridone are known to modulate components of dopamine
neurotransmission. Lithium inhibits pre-synaptic dopamine
release. Risperidone, by blocking dopamine receptors,
inhibits a different component of dopamine neurotrans-
mission. In theory, this “two-pronged” effect causing in-
hibition of dopamine neurotransmission by the combina-
tion of lithium and risperidone would result in profound
dopaminergic hypofunctionality, reflected for example by
extrapyramidal symptoms [16]. Furthermore, it should be
mentioned that risperidone is very similar to haloperidol
pharmacologically and in higher dosages also clinically, and
thus, compared to other atypical antipsychotics, the risk of
developing neurotoxic symptoms under a combination with
lithium is higher.
Concerning lithium antipsychotic combinations,
in general it was found that neurotoxic syndromes may
already occur with normal levels of lithium but signifi-
cantly more often in combination with antipsychotics in
particular [17–19]. Miller and Meninger presumed that a
dose dependency of the neurotoxic symptoms exists for the
antipsychotics but not for lithium levels [20].
Case 2 reported on a 72-year-old depressive male pa-
tient, who developed neurotoxic symptoms under a com-
bination of lithium, trazodone and bupropion. Both tra-
zodone and bupropion were given at maximal doses, and
it should be noted that this has to be considered as an off-
label situation, which already bears some risk per se without
lithium. There is little experience concerning the combina-
tion of lithium and bupropion and so far not much is known
about possible interaction mechanisms. Part of bupropion’s
action may be attributed to the inhibition of dopamine re-
uptake that may induce organic mental disorders in certain
susceptible patients. Dose-related dopaminergic augmenta-
tion, accumulation of toxic metabolites and a predisposition
to psychosis and drug interactions are suggested as possible
mediatingmechanisms for neurotoxic syndromes in patients
with bupropion medication [21, 22].
Figure 1
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In the current case, serotonergic side effects should also
be considered. The combination of trazodone, inhibiting
the serotonin re-uptake, with lithium, which is known to
elevate the release of serotonin, might facilitate the develop-
ment of a serotonin syndrome.
The resulting neurotoxic symptoms seen in case 2 could
possibly be the result of an interaction between bupropion
and trazodone. For example, trazodone is metabolised by
cytochrome P450 to the active metabolite mCPP (m-chlor-
phenylpiperazine) which itself is a substrate of CYP 2D6.
Bupropion is an inhibitor of CYP 2D6, which means that the
level of mCPP is increased by co-medication [23]. mCPP is
known to produce anxiety, derealisation and depersonali-
sation.
Finally, case 3 described a 71-year-old female patient
with a bipolar-II disorder, who manifested neurotoxic
symptoms after being given a combination of lithium and
tranylcypromine. No reports on the combination and inter-
action between the two drugs can be found in the literature.
Again dopaminergic effects could be the cause of neurotoxic
symptoms as tranylcypromine influences dopamine levels
which may block its breakdown.
Lithium probably also influences the dopaminergic
system. On the basis of data from animal studies, it may
be assumed that dopamine (DA) release in the nucleus
accumbens is reduced in subjects treated chronically with
lithium, and this effect is maintained for three days after
withdrawal from lithium treatment [24]. Furthermore,
there is some evidence that decreased dopamine release
may mediate the mood-stabilising action of lithium [25].
Findings from other studies indicate that not all mood-sta-
bilising agents, but only those which have anticonvulsant
mood-stabilising properties, increase DA release in the cor-
tex and that the effect is dependent upon 5-HT(1A) receptor
stimulation [26]. Further studies suggest that lithium may
exert some of its effects not by directly inhibiting enzymes,
but by destabilising specific protein complexes involved in
the regulation of enzyme activity [27]. Taken together, the
complex molecular mechanisms of action involved in the
interaction of lithium and DA are still unknown.
In general, the probability of developing signs of lith-
ium intoxication in patients treated with lithium increases
with advanced age, co-morbidity with pre-existing neuro-
logical or other general diseases, especially those associated
with fever, and in combination with the use of antipsychot-
ics, antidepressants or mood stabilisers. The serum lithium
level is not necessarily a reliable indication for intoxica-
tion [4, 28]. In this paper, we also report on elderly patients
(60–72 years of age) who had co-morbid somatic illnesses
such as thyroid insufficiency, renal insufficiency and symp-
toms similar to those seen in Parkinson Disease, and took
the appropriate medication. In all our three cases, lithium
levels were constantly within the normal range. It must be
conceded, however, that elderly patients, and particularly
patients with impaired kidney function, can manifest toxic
effects despite normal lithium levels.
The EEG has proven to be the most important diagnostic
standard for the monitoring of neuropsychiatric effects. As
the neuropsychiatric encephalopathic reactions to lithium or
a combination of lithium and antipsychotics or antidepres-
sants are probably an overall cortical reaction to lithium, the
EEG as a functional indicator of the whole cortical activity
can offer valuable information [29]. In any case, there is a
strong correlation between pathological EEG changes and
neuropsychiatric encephalopathic reactions to therapy with
lithium and antipsychotics or antidepressants.
The patients in all three cases showed pathological EEG
patterns in the acute state which improved after stopping the
medication. However, EEG examinations were only carried
out after, and not before, medication was given. Typical EEG
changes under lithium intoxication, which were also seen in
our three cases, are slowed baseline activity, increased theta
and delta waves and a tendency towards synchronisation,
and sometimes even paroxysms.
Triphasic repetitive potentials may also occasionally be
seen. However, it has to be stated that these changes are
not specific for lithium intoxication. It should be mentioned
that similar EEG changes can also be observed under intox-
ication with antipsychotics or antidepressants [30]. Frontal
Intermittent Rhythmic Delta Activity (FIRDA), as observed
in case 1, can also occur in patients with chronic, mostly
ischemic structural brain lesions during acute metabolic
derangement [31].
Several reports suggest a closer relationship between
neurotoxic symptoms with EEG changes than with serum
levels of lithium. This is of clinical interest with respect
to encephalopathic reactions under therapeutic serum
levels. The phenomenon of long-lasting EEG changes after
discontinuation of lithiummay be due to neuronal storing of
lithium and persisting neurological disturbances [32].
In patients treated with lithium, EEG has the potential
to differentiate between encephalopathy and non-convul-
sive status epilepticus, but more clearly can be used to fol-
low up a patient’s clinical course as lithium levels fall (after
stopping lithium treatment) in the setting of a multifactorial
encephalopathy [33].
Conclusion
Summing up, it can be concluded that while the therapeu-
tic efficacy of lithium is invaluable, it can cause a variety of
neurotoxicities, even at normal therapeutic doses or con-
centrations. The drug interaction effect is an important
factor, especially in combination with antipsychotics, anti-
depressants and mood-stabilisers. Neurotoxic syndromes
can occur both during an increase and reduction of anti-
psychotics or antidepressants under continuous lithium
therapy and during additional application of lithium to
an existing antipsychotic or antidepressive treatment. The
mono-therapy with an atypical antipsychotic or an anti-
depressant represents a therapeutic alternative.
In patients developing neurotoxic symptoms un-
der lithium therapy, further investigations should include
serum levels and an EEG, which represents a simple and
important investigational method. As soon as neurotoxic
symptoms manifest, the psychopharmacotherapy should be
stopped immediately. After the disappearance of the neuro-
toxic symptoms, further developments should be care-
fully monitored and documented and laboratory tests and
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follow-up EEGs should be carried out. In addition, further
neuropsychological examinations are recommended.
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